TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers.

Rajat ThawaniMatteo RepettoClare KeddyKatelyn NicholsonKristen JonesKevin NusserCatherine Z BeachGuilherme HaradaAlexander DrilonMonika A Davare

Published in: bioRxiv : the preprint server for biology (2024)

resistance setting. In addition, we show activity of the pyrazine carboxamide-based type I TKI, gilteritinib, in ROS1 L2086F resistance, suggesting that gilteritinib could be another option for ROS1 L2086F TKI-resistant patients. This study represents the first comprehensive report of ROS1 L2086F in the context of later-generation TKIs, including the macrocyclic inhibitors.

Keyphrases

cell death
reactive oxygen species
dna damage
tyrosine kinase
end stage renal disease
advanced non small cell lung cancer
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
chronic myeloid leukemia
patient reported outcomes
epidermal growth factor receptor